Terns Pharmaceuticals(TERN)

Focus: Terns Pharmaceuticals is a publicly traded, small-molecule focused biotech company headquartered in Foster City, CA, specializing in liver disease and metabolic disorders with a clinical-stage pipeline.

Neurology

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Terns Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Terns Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

TERN-201

NASH - Nonalcoholic Steatohepatitis

PHASE_1

Clinical Trials (1)

NCT04897594AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

Phase 1

Help build intelligence for Terns Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a focused pipeline in high-demand therapeutic areas: NASH (3 programs), obesity, and oncology address large unmet medical needs with commercial potential
Public company stability with $161M cash position (FY 2025) provides runway for clinical development without immediate funding pressure
Lean organization (1 active job posting suggests small, nimble team) offers opportunity for broad responsibility and impact on key programs

Watch Out For

Pre-revenue stage with consistent operating losses ($89-90M annually) creates execution risk and limited near-term commercial upside
No Phase 3 programs or approved products means earliest realistic revenue inflection is 3+ years away, with no near-term liquidity events
Minimal hiring activity (1 open role) signals constrained growth; career progression may be limited in a small, capital-efficient organization

Generated by Claude from Terns Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

TERN-701

Chronic Myeloid Leukemia, Chronic Phase

PHASE_1_2

Clinical Trials (1)

NCT06163430A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

Phase 1/2

TERN-501

NASH - Nonalcoholic Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT05415722DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

Phase 2

TERN-101

NASH - Nonalcoholic Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT04328077LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

Phase 2

TERN-601

Overweight or Obesity

PHASE_2

Clinical Trials (1)

NCT06854952A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Infectious Diseases, Metabolic Diseases, Oncology

Publications: 8 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Infectious Diseases

3 pipeline

Metabolic Diseases

1 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$70M10%

Net Income

-$89M

Cash

$161M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(8)

Recent peer-reviewed publications with author affiliations at this company

Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development.

EBioMedicine

2026

PMID:41547115

TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial.

Showing 5 of 8 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Terns Pharmaceuticals(TERN)

About Terns Pharmaceuticals

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Terns Pharmaceuticals(2)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Research Publications(8)